Differentiating Primary Mood Disorders from Affective Symptoms in Substance Abuse
neuroscienceCME Medical Simulation
 | Patient Info: Barbara, a 48-year-old mid-level manager, presents with complaints about not being able to "keep up" and being reluctant to go with friends due to feelings of inadequacy. She reports that her weekend relaxation is staying at home on the weekends and having some wine with her husband. |
This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (CNE)
- Pharmacists (ACPE)
Credit Expiration Date:
Friday, January 8, 2010
 | Kyle M. Kampman, MD Associate Professor, Department of Psychiatry University of Pennsylvania School of Medicine Medical Director, University of Pennsylvania Treatment Research Center Medical Director, Charles O'Brien Center for the Treatment of Addictions Philadelphia, PA |
For individuals with alcohol dependence and co-occurring mental disorders, the presentation can be complex. Each disorder may affect the individual's ability to engage in and respond to therapy. For example, Buckner and colleagues investigated social anxiety disorder (SAD) and found over a 14-year period that SAD at study entry was associated with 4.5 greater odds of alcohol dependence at follow-up.(1)
And, in the National Epidemiologic Survey on Alcohol and Related Conditions study, Grant and colleagues found that the odds ratio was 4.1 for a patient with alcohol dependence to have any mood or anxiety disorder compared with the general population.(2)
For patients with alcohol dependence and co-occurring mental disorders, treatment plans need to integrate psychosocial support pharmacotherapy for both disorders. The Substance Abuse and Mental Health Services Administration has created treatment principles that focus on the need for individualized treatment for each patient and recognize the need to adequately identify, diagnose, and then treat patients with co-occurring disorders.(3)
Clinicians need ready access to evidence-based data to help diagnose and treat patients with alcohol dependence and co-occurring mental disorders. This interactive, case-based learning tool offers a unique opportunity for clinicians to further develop their problem-solving skills, benefit from the input and expertise of experienced faculty, and to practice real-world clinical skills as they explore the integration of pharmacotherapy and psychosocial treatment to improve outcomes for patients with alcohol dependence.
- Buckner JD, Schmidt NB, Lang AR, Small JW, Schlauch RC, Lewinsohn PM. Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res 2008;42:230-239.
- Grant BF, Stinson SF, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:807-816.
- SAMHSA’s Co-Occurring Center for Excellence (COCE) Overview Paper Number 3. Overarching Principles To Address the Needs of Persons With Co-Occurring Disorders. Available at: http://coce.samhsa.gov. Accessed November 13, 2008.
To evaluate evidence-based psychosocial interventions and pharmacotherapy management strategies to improve outcomes for patients with alcohol dependence.
At the end of this CE activity, participants should be able to:
- Identify the diagnostic challenges in patients who may present with alcohol dependence and co-occurring mental disorders.
- Evaluate screening tools and medication regimens that may be useful for patients with alcohol dependence and co-occurring disorders.
- Utilize effective, evidence-based treatment strategies to improve overall outcomes in patients with alcohol dependence and co-occurring disorders.
Physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals interested in management and treatment of patients with alcohol dependence.
CME Outfitters, LLC, gratefully acknowledges an independent educational grant from Cephalon, Inc., and Alkermes, Inc., in support of this CE activity.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME Outfitters, LLC, designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.
CNE Credit (Nurses):
CME Outfitters, LLC, is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
It has been assigned code 6WASUP-PRV-0650. 0.5 contact hours will be awarded upon successful completion.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs)
Universal Program Number: 376-000-09-001-H04-P
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations can be completed online at www.neuroscienceCME.com (click on the Testing/Certification link under the Activities tab - requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet
Explorer for Mac. For complete technical requirements and
privacy policy, visit www.neuroscienceCME.com/technical.asp.
Kyle M. Kampman, MD, Guest Host
A board-certified psychiatrist specializing in addiction psychiatry, Dr. Kyle M. Kampman, MD, received his medical degree from Tulane University School of Medicine. He interned at the National Naval Medical Center in Bethesda, Maryland, and served as a general medical officer in the Navy until 1990. He completed his residency in psychiatry and fellowship in addiction psychiatry at the University of Pennsylvania.
Currently, Dr. Kampman is Medical Director of the Charles O’Brien Center for the Treatment of Addictions, Associate Professor of Psychiatry, and Medical Director of the Treatment Research Center at the University of Pennsylvania in Philadelphia. His research interests include pharmacotherapy for cocaine dependence and the cocaine withdrawal syndrome.
Dr. Kampman and his colleagues at the Treatment Research Center developed a scale that measures cocaine withdrawal symptom severity, the Cocaine Selective Severity Assessment (CSSA). He has written several papers showing that cocaine withdrawal symptom severity, measured by this scale, can predict outcome in cocaine dependence treatment. He has also used this scale to identify a subgroup of cocaine dependent patients who appear to respond well to medications aimed at reducing cocaine withdrawal symptoms such as amantadine and propranolol.
Dr. Kampman completed a successful pilot trial of topiramate for relapse prevention in the treatment of cocaine dependence. Based on the positive results of the pilot study and results from the University of Texas showing topiramate's efficacy for the treatment alcohol dependence, Dr Kampman received a grant from NIAAA funding a study of topiramate for alcoholism and comorbid cocaine dependence.
Dr. Kampman has participated in a number of clinical trials of medications fro the treatment of alcohol dependence. Most recently, he published the results of a successful trial of quetiapine for the treatment of alcoholism. He is currently conducting a NIAAA funded follow-up trial examining the usefulness of quetiapine for the treatment of frequent heavy drinkers.
Dr. Kampman serves on the editorial board of the Journal of Addiction Medicine and is an active member of the American Society of Addiction Medicine, College on Problems of Drug Dependence, and the Pennsylvania Society of Addiction Medicine. His contributions to the field have been acknowledged by the Scott Mackler Award for Excellence in Substance Abuse Teaching presented by the University of Pennsylvania School of Medicine and the Caron Foundation’s Medical Professional-Physician Award.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all its CE activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kampman has disclosed that he receives grants/research support from Alkermes, Inc. He serves as a consultant to Cephalon, Inc., Forest Pharmaceuticals, and Reckitt Benckiser Group plc.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, Cephalon, Inc., and Alkermes, Inc., do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PL-017-010809-15
